Genmab A/S annual net profit margin
2022
2023
2024
2025
Genmab A/S Net Profit Margin Growth & History (GMAB)
Genmab A/S's net profit margin was 25.89% for fiscal 2025.
View full Genmab A/S company overviewGenmab A/S annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 25.89% | −10.42 pp |
| 2024 | 2024-12-31 | 36.30% | +9.90 pp |
| 2023 | 2023-12-31 | 26.40% | −11.19 pp |
| 2022 | 2022-12-31 | 37.59% | — |
Genmab A/S quarterly net profit margin
Q2.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 26.23% | −10.09 pp |
| Q1 2026 | 2026-03-31 | 5.92% | — |
| Q4 2025 | 2025-12-31 | 2.93% | — |
| Q3 2025 | 2025-09-30 | 39.24% | — |
| Q2 2025 | 2025-06-30 | 36.32% | +10.27 pp |
| Q2 2024 | 2024-06-30 | 26.06% | — |
Genmab A/S net profit margin trends
Between the periods ended 2022-12-31 and 2025-12-31, Genmab A/S's net profit margin decreased from 37.59% to 25.89%, a change of −11.70 percentage points. The latest reported quarter, Q2 2026, shows 26.23%.
About the metric
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
Calculation and source
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Genmab A/S source filings ↗Community posts
Genmab reports mature survival data for petosemtamab in head and neck cancer
Genmab ($GMAB) reported median overall survival of 28.2 months with petosemtamab plus pembrolizumab in a Phase 2 study of previously untreated, recurrent or metastatic PD-L1-positive head and neck cancer. Among 43 patients evaluable for eff ...
Genmab and Incyte agree colorectal-cancer combination trial
Genmab ($GMAB) and Incyte ($INCY) agreed to test a three-part treatment approach in previously untreated metastatic colorectal cancer carrying a KRAS G12D mutation. The planned Phase 1/2 study combines Genmab’s petosemtamab, an antibody tar ...
